Koselugo Fasting Update

Author: Koselugo

Published On: 03/29/2024

Koselugo is the FIRST and ONLY FDA-approved treatment shown to reduce the size of plexiform neurofibromas (PN)*. Koselugo has been shown to shrink plexiform tumors in children aged 2 years and older. In a clinical study, 66% or 33 of 50 patients in the clinical study saw their plexiform neurofibromas (PN) shrink, and 82% or 27 of 33 patients who responded continued to benefit for at least one year.

Recent developments have improved the format in which patients can take the drug. Koselugo can now be taken on an empty stomach or with food to allow for more flexibility in daily life. Click the PDF below to learn more and consult with a Patient Education Manager. You can also connect and learn more on the Koselugo site.